Led · Equity · Jul 2025

Peachies builds a premium, design-first nappy product sold primarily via a frictionless subscription model and complemented by parent-focused service design. The brand positions itself as a modern, hospitality-inspired alternative in a commoditised category and has formed collaborations with challenger brands TRIP and Oddbox. Peachies reports 10x revenue growth in 2024 and has reached over 25,000 families, with an organic reach of more than 4M. Founders emphasise reducing parental overwhelm by delivering time- and peace-of-mind benefits through product and service design. The company is scaling its operations and digital infrastructure to support accelerated growth and further expansion of its subscription service. Peachies makes premium, environmentally friendly nappies sold via a monthly home-delivered subscription. Launched in 2023 and based in London, the company positions itself as a category innovator focused on product quality and customer service. Climate-KIC’s Impact Forecast cited that every 1,000 babies wearing Peachies nappies saves the equivalent weight of 17 elephants. Peachies says it has been backed from the start by founders, industry executives and experienced investors, and has now added renowned funds to its cap table. The brand plans to use the fundraising to accelerate growth in the UK, expand its product range and scale a nappy concierge service. The company recently completed a fundraising round that secured £1.4 million to support those priorities.

Participated · Series D · Jul 2012

Bluebird bio is building a gene-therapy platform that inserts a functional copy of a disease-causing gene into a patient’s own hematopoietic stem cells using lentiviral vectors, eliminating the complications of donor transplants. Its lead clinical asset, LentiGlobin, is in an ongoing Phase 1/2 study for beta-thalassemia and sickle cell anemia and has shown the potential to end lifelong transfusions according to data published in Nature. The company also has a later-stage program for childhood cerebral adrenoleukodystrophy. Operations are split between Cambridge, MA and Paris, and the firm is privately held with backing from Third Rock Ventures, TVM Capital, Forbion Capital Partners, Easton Capital and Genzyme Ventures. Beyond internal R&D, bluebird bio collaborates with Généthon to advance lentiviral manufacturing. Its strategy centers on delivering one-time, curative treatments for rare blood and neurological disorders, and the latest non-dilutive funding strengthens its clinical and manufacturing capabilities. No commercial revenue has been disclosed in the article.